



# INSTITUTIONAL BIOSAFETY COMMITTEE

---

## UNIVERSITY *of* WASHINGTON

### Meeting Minutes

**Date:** Wednesday, August 19, 2015

**Time:** 10:00 A.M. – 12:00 P.M.

**Location:** Foegen N-130A

- Members Present:**
1. Thea Brabb, Comparative Medicine (*Animal Containment Expert*)
  2. William Glover, Washington State Public Health Laboratories (*Community Member*)
  3. Jean Haulman, UW Travel Clinic
  4. David Koelle, Allergy and Infectious Diseases
  5. Stephen Libby, Laboratory Medicine (*IBC Chair*)
  6. Jeanot Muster, Pharmacology
  7. Angela Rasmussen, Microbiology
  8. Jason Smith, Microbiology
  9. Eric Stefansson, Environmental Health & Safety (*Biosafety Officer*)
  10. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)

#### Commonly Used Abbreviations

IBC: Institutional Biosafety Committee

BSO: Biological Safety Officer

BUA: Biological Use Authorization

BSL: biosafety level

PI: Principal Investigator

IACUC: Institutional Animal Care and Use Committee

NIH: National Institutes of Health

DURC: Dual Use Research of Concern

SOP: standard operating procedure

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:02 a.m. A quorum was present.
2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.
3. **APPROVAL OF MINUTES:**
  - The IBC Chair sought a motion to approve the minutes from the July 15, 2015 minutes meeting.
  - A member made a motion to approve the July 15, 2015 minutes. Another member seconded the motion.
  - The committee voted unanimously, with three abstentions, to approve the July 15, 2015 meeting minutes.
4. **BIOSAFETY OFFICER (BSO) REPORT:** The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the *NIH Guidelines*, (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.
  - a. Biosafety Officer Report
    - The IBC Chair sought a motion to approve this month's Biosafety Officer Report.
    - Dr. Clark added plasmid DNA in macaques.
    - Dr. Dacey added the use of human source material.
    - Dr. Miller transferred two previously approved agents from one BUA to another BUA.
    - Dr. Katze added sterile RNA derived from an influenza virus to his approval.
    - Dr. Yager added non-recombinant *Neisseria gonorrhoeae* to his BUA.
    - Dr. Shen, Dr. Singh, and Dr. McCune each renewed a BUA involving human source material.
    - Dr. Haeseleer renewed a BUA involving human and non-human primate source material.
    - Dr. Lingappa and Dr. Hinds each initiated a new research project involving human source material.
    - Dr. Woodward added a new room to his approval.
    - Dr. Sniadecki added several new rooms to his approval.
    - Dr. Klatt received a new BUA letter involving Risk Group 1 agents used in macaques.
    - Dr. Holmes renewed a BUA involving non-recombinant *Neisseria* strains and *Trichomonas vaginalis*.
    - A member made a motion to approve this month's Biosafety Officer Report. Another member seconded the motion.
    - The Committee unanimously voted to approve this month's Biosafety Officer Report.
5. **CATEGORY III-D AMENDMENTS**
  1. Gire, David, change, *Neural circuit mechanisms of odor localization*
    - The biosafety officer presented the project.

- The lab studies the mechanisms through which the brain integrates and processes information during naturalistic sensory-guided behaviors.
  - The investigator is already approved for AAV (adeno-associated viral vectors) in mice. He now wants to use AAV in rats. Some new rooms are also being added.
  - The assigned IBC member endorsed the biosafety officer's review.
  - The draft BUA letter was shown.
  - The assigned IBC member made a motion to approve the draft BUA for Dr. Gire. A second is not needed since he endorsed the review.
  - The Committee voted unanimously to approve the draft BUA for Dr. Gire, pending the lab inspection.
2. Moritz, Chet, change, *Combined Stem Cell Transplantation and Targeted Microstimulation to Direct the Formation of Functional Connections and Neural Repair*
- The biosafety officer presented the project.
  - The lab is studying how proprioception is represented in the activity of neurons within the brain.
  - The investigator is already approved for AAV in rats. He now wants to use AAV in mice. Some new rooms are also being added.
  - The assigned IBC member endorsed the biosafety officer's review.
  - The training has been completed, and the lab inspection is scheduled for later in the week.
  - The draft BUA letter was shown.
  - The assigned IBC member made a motion to approve the draft BUA for Dr. Moritz. A second is not needed since he endorsed the review.
  - The Committee voted unanimously to approve the draft BUA for Dr. Moritz, pending the lab inspection.

## 6. INDIVIDUAL PROJECT REVIEWS

3. Oberst, Andrew, change, *Programmed Cell Death and Immunity*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - The lab researches how different forms of cell death occur, and how they influence immune responses.
  - This is a change. The investigator is requesting to add vaccinia virus, for use in vitro.
  - The procedures outlined in the newly approved Vaccinia Virus Research Safety Policy are being followed. The strains of vaccinia that Dr. Oberst is working with are not highly attenuated. Therefore, personnel with direct contact with these strains (as defined in the policy) are required to receive medical counseling and be offered the vaccinia vaccination.
  - The Oberst lab has written SOPs in place for working with vaccinia.
  - The lab has been inspected, and the training is completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Oberst. A second is not needed since she is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Oberst.
4. Albers, John, renewal, *Phospholipid Transfer Proteins*
- The assigned IBC Primary Reviewer presented the Primary Review.

- The overall goal of the project is to test mechanisms and effects of different lipid transfer proteins on metabolism of lipids and lipoproteins in cells and in vitro systems.
  - The lab uses lentiviral vectors and human source material.
  - The lab has been inspected, and the training is completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Albers. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Albers.
5. Childers, Martin, new, *Gene therapy in canine XLMTM*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - The lab studies XLMTM (X-linked myotubular myopathy), a fatal pediatric disease of skeletal muscle. The overall goal of this research is to test a gene replacement therapy in a canine model of myopathy.
  - This is a new project from an established investigator. AAV will be used in dogs. ABSL-1 (animal biosafety level 1) containment will be used.
  - The draft BUA letter was shown.
  - The lab has previously been inspected, and the training has been taken.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Childers. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Childers.
6. Dickson, Rose, new, *Calcium signaling and excitation contraction coupling in cardiac muscle*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - The lab studies the mechanisms controlling calcium signaling and excitation contraction coupling in cardiac muscle cells.
  - Human cells and AAV are used on this project.
  - The draft BUA letter was shown.
  - The lab was inspected, and the training is completed.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Dickson. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Dickson.
7. Hampe, Christiane, change, *Autoantibodies and Anti-idiotypic Antibodies in Type 1 Diabetes*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - The lab utilizes in vitro and mouse models to develop novel therapies for Type 1 diabetes.
  - The investigator is requesting to add AAV both in vitro and in mice.
  - The draft BUA letter was shown.
  - The investigator is adding a new room, which was inspected by the biosafety officer. The training has been completed.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hampe. A second is not needed since she is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Hampe.
8. Kiem, Hans-Peter, renewal, *Strategies to Improve Hematopoietic Stem Cell Expansion*
- The assigned IBC Primary Reviewer presented the Primary Review.

- The overall goal of the project is to develop new treatment strategies for blood diseases.
  - Lentiviral vectors are used in macaques.
  - The draft BUA letter was shown.
  - A discussion occurred regarding the BUA application question that asks about the greatest biohazard.
  - The lab has been inspected, and the training has been taken.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kiem. A second is not needed since she is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Kiem.
9. Kwon, Ronald, change, *Viral injections into regenerating zebrafish fins*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - The lab studies skeletal genes that are involved in bone formation and osteoblast differentiation.
  - The investigator is requesting to add a herpes simplex viral vector, for use in vitro and in zebrafish.
  - The pilot testing will be done with a herpes vector obtained from a collaborator at the UW. These vectors have already tested negative for replication competent virus (RCV). The investigator also wants to use vectors from a collaborator at MIT. These vectors have not yet been RCV tested. The investigator has added a BSL-2 room to his approval so that he can perform the RCV testing before the vectors are administered to the zebrafish.
  - Only RCV-negative herpes viral vectors can be used in the zebrafish because the investigator doesn't have ABSL-2 zebrafish housing.
  - The lab has been inspected, and the training has been completed.
  - The draft BUA letter was shown.
  - The IACUC protocol has not been submitted. The BUA letter will need to be held until the biosafety officer has reviewed the IACUC protocol.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kwon. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Kwon, pending submission of the IACUC protocol.
10. Marrazzo, Jeanne, change, *Horizontal Gene Transfer in Chlamydia*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - The investigator is adding a new strain of recombinant *Chlamydia trachomatis*.
  - We have received a letter from the NIH confirming that this modification of *Chlamydia* does not fall under Section III-A of the NIH Guidelines.
  - The lab inspection has been completed, and the training has been taken.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Marrazzo. A second is not needed since he is the Primary Reviewer.
  - The Committee voted unanimously to approve the draft BUA for Dr. Marrazzo.
11. Cirulli, Vincenzo, renewal, *Role of Cell Adhesion Molecules In Islet Biology*
- The assigned IBC Primary Reviewer presented the Primary Review.

- The overall goal of the research is to generate insulin-producing cells from human stem cells as a potential cell-based replacement therapy for diabetes.
- Biohazardous agents used on the project include AAV, lentiviral vectors, human cells, and feline immunodeficiency virus.
- The investigator needs to clarify whether he is creating cDNA libraries (question 29 on the BUA application).
- The draft BUA letter was shown.
- The lab has been inspected, and the training has been taken.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Cirulli. A second is not needed since he is the Primary Reviewer.
- The Committee voted unanimously to approve the draft BUA for Dr. Cirulli, pending clarification of question 29 on the BUA application.

**12. Raskind, Wendy, change, *Spinocerebellar-Ataxia Type 14: Animal models of human disease***

- The assigned IBC Primary Reviewer presented the Primary Review.
- The lab seeks to identify and study genes responsible for neurobehavioral disorders.
- This is a change. The investigator is requesting to add AAV and CAV (canine adenoviral vectors) for use in vitro and in mice.
- The lab has previously been inspected, and the training records are up-to-date.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Raskind. A second is not needed since he is the Primary Reviewer.
- The Committee voted unanimously to approve the draft BUA for Dr. Raskind.

**13. de la Iglesia, Horatio, renewal, *Neural Control of Circadian Rhythms***

- The assigned IBC Primary Reviewer presented the Primary Review.
- The lab seeks to understand how the circadian system regulates behavioral and physiological rhythms.
- Adeno-associated viral vectors in mice are used on this project.
- A discussion occurred regarding whether owl monkeys are used on the project. The investigator receives shipments of owl monkey fecal samples, sent from a collaborator in another state. The committee discussed the potential biohazard risks associated with New World primate feces. The biosafety officer will find out whether there will be owl monkey feces left over, and if so, the investigator will be directed to autoclave the waste.
  - *Post-Meeting Update: The investigator will autoclave any owl monkey fecal material.*
- The lab has been inspected, and the training has been taken.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. de la Iglesia. A second is not needed since he is the Primary Reviewer.
- The Committee voted unanimously to approve the draft BUA for Dr. de la Iglesia.

**14. Wills, Andrea, new, *Molecular mechanisms of regeneration in *Xenopus tropicalis****

- The assigned IBC Primary Reviewer presented the Primary Review.
- The overall goal of the research is to identify the molecular process that enable or constrain the ability of tissues to regenerate.

- This project involves breeding and using transgenic *Xenopus tropicalis*, a frog species in which tadpoles are able to regenerate the spinal cord, muscle, cartilage and vasculature, but lose this ability as they mature.
- The training has been taken, but the lab has not yet been set up. The biosafety officer will inspect the lab once it is ready.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Wills. A second is not needed since he is the Primary Reviewer.
- The Committee voted unanimously to approve the draft BUA for Dr. Wills, pending completion of the lab inspection.

#### **SUBCOMMITTEE UPDATES:**

##### **15. Katze, Michael, new, *Characterization of host responses to SARS-CoV using a cell culture model***

- An IBC member gave a status update about this project. The project is awaiting occupational health recommendations. Employee Health Center is working with Harborview to develop policies and procedures that would be enacted if a potential exposure was suspected, or a researcher working on the project became symptomatic. The subcommittee will review the science of the project and these occupational health recommendations and policies simultaneously.

#### **FOR YOUR INFORMATION:**

- Dual Use Research of Concern Policy Implementation Update
  - The United States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern is effective on September 24<sup>th</sup>. EH&S and the DURC Institutional Review Entity (IRE) have been working on several implementation steps. The DURC application (required for any investigator working with one or more of the agents covered under the DURC policy) is now online. An online training course about DURC was developed and is currently undergoing testing. It is expected to be live next week.
  - Outreach emails will be sent to the EH&S biosafety mailing list, which includes all principal investigators and lab managers. Emails will also be sent to MyChem account holders, MRAM (500+ research administrators), all UW deans, directors, and chairs, and all investigators and personnel working with select agents.

#### **ISSUES FROM THE FLOOR & PUBLIC COMMENTS:**

There were no issues from the floor, and no public comments.

#### **MEETING ADJOURNED AT APPROXIMATELY 11:45 a.m.**